LitAlert ~~ GeneLit.com

    • A commentary on the discrepancy between blood and tumour BRCA testing: an open question.
    • De Paolis E, Marchetti C, Concolino P, Scambia G, Urbani A, Fagotti A, Minucci A.
    • BJOG. 2022 Mar 23. doi: 10.1111/1471-0528.17158. Epub ahead of print.
    • Commentary
    • Combining Carbon-Ion Irradiation and PARP Inhibitor, Olaparib Efficiently Kills BRCA1-Mutated Triple-Negative Breast Cancer Cells.
    • Kawanishi M, Fujita M, Karasawa K.
    • Breast Cancer (Auckl). 2022 Mar 23;16:11782234221080553. doi: 10.1177/11782234221080553.
    • Intention to Inform Relatives, Rates of Cascade Testing, and Preference for Patient-Mediated Communication in Families Concerned with Hereditary Breast and Ovarian Cancer and Lynch Syndrome: The Swiss CASCADE Cohort.
    • Sarki M, Ming C, Aissaoui S, Bürki N, Caiata-Zufferey M, Erlanger TE, Graffeo-Galbiati R, Heinimann K, Heinzelmann-Schwarz V, Monnerat C, Probst-Hensch N, Rabaglio M, Zürrer-Härdi U, Chappuis PO, Katapodi MC; on behalf of the CASCADE Consortium.
    • Cancers (Basel). 2022 Mar 23;14(7):1636. doi: 10.3390/cancers14071636.
    • Tumor BRCA Testing in Epithelial Ovarian Cancers: Past and Future—Five-Years’ Single-Institution Experience of 762 Consecutive Patients.
    • Fumagalli C, Betella I, Rappa A, di Giminiani M, Gaiano M, De Vitis LA, Zambetti B, Vacirca D, Multinu F, Venetis K, Colombo N, Barberis M, Guerini Rocco E.
    • Cancers (Basel). 2022 Mar 23;14(7):1638. doi: 10.3390/cancers14071638.
    • One Size Does Not Fit All: Breast Cancer in Young Women.
    • Yehia L, Eng C.
    • Clin Cancer Res. 2022 Mar 23:clincanres.0352.2022. doi: 10.1158/1078-0432.CCR-22-0352. Epub ahead of print.
    • Commentary
    • Study: New tool to predict breast cancer risk for Black women.
    • [No author given]
    • FORCE. XRAY. 2022 Mar 22.

    Original research:

    A Validated Risk Prediction Model for Breast Cancer in US Black Women.

    • Olaparib beyond progression compared with platinum chemotherapy after secondary cytoreductive surgery in patients with recurrent ovarian cancer: phase III randomized, open-label MITO 35b study, a project of the MITO-MANGO groups.
    • Schettino C, Musacchio L, Bartoletti M, Chiodini P, Arenare L, Baldassarre G, Califano D, Capoluongo E, Costi MP, D'Incalci M, Marchini S, Mezzanzanica D, Normanno N, Scala S, Greggi S, Perrone F, Pignata S.
    • Int J Gynecol Cancer. 2022 Mar 22:ijgc-2022-003435. doi: 10.1136/ijgc-2022-003435. Epub ahead of print.
    • Study protocol

    Clinical Trials: MITO 35B: Olaparib Beyond Progression Compared to Platinum Chemotherapy After Secondary Cytoreductive Surgery in Recurrent Ovarian Cancer Patients. (MITO 35B) (ClinicalTrials.gov)

    • Can Automated Alerts in the Electronic Health Record Encourage Referrals for Genetic Counseling and Testing Among Patients at High Risk for Hereditary Cancer Syndromes?
    • Zorn KK, Simonson ME, Faulkner JL, Carr CL, Acuna J, Hall TL, Jenkins JF, Drummond KL, Curran GM.
    • JCO Oncol Pract. 2022 Mar 22:OP2100641. doi: 10.1200/OP.21.00641. Epub ahead of print.
    • You Don’t Have a BRCA Mutation, But Could You Have Lynch Syndrome?
    • [No author given]
    • My Gene Counsel. Genetic Journal. 2022 Mar 22.
    • DNA repair defects in cancer and therapeutic opportunities.
    • Hopkins JL, Lan L, Zou L.
    • Genes Dev. 2022 Mar 1;36(5-6):278-293. doi: 10.1101/gad.349431.122.
    • Review